Sam Brusco, Associate Editor12.13.22
Axonics has earned Health Canada approval for its fourth-generation R20 rechargeable sacral neuromodulation system.
The newly-approved Axonics R20 neurostimulator can remain in the body for at least 20 years and reduces the frequency of recharging the implanted device to once every six to 10 months for only an hour. The third generation’s recharging interval was once a month for an hour.
The Axonics R20 neurostimulator has the same small 5cc form factor as the third-gen device and is paired with the same tined lead and intuitive remote patient control.
“Since Axonics’ founding, delivering superior patient experiences has been at the forefront of our development efforts,” Raymond W. Cohen, CEO of Axonics told the press. “Patients with overactive bladder want efficacy and a long-lived solution to address their chronic condition. The Axonics R20 represents a significant breakthrough for rechargeable neuromodulation devices and underscores our commitment to continuous innovation. We are confident that Axonics’ keen focus on the incontinence patient population and increasing public awareness of sacral neuromodulation has the potential to drive significant market expansion in the years ahead.”
Axonics began sales of the R20 sacral neuromodulation system to Canadian customers. The device is currently under FDA review and the company expects approval and plans to launch the product in the U.S. in Q1 2023.
The company rolled out its F15 recharge-free sacral neuromodulator in the U.S. in April 2022.
The newly-approved Axonics R20 neurostimulator can remain in the body for at least 20 years and reduces the frequency of recharging the implanted device to once every six to 10 months for only an hour. The third generation’s recharging interval was once a month for an hour.
The Axonics R20 neurostimulator has the same small 5cc form factor as the third-gen device and is paired with the same tined lead and intuitive remote patient control.
“Since Axonics’ founding, delivering superior patient experiences has been at the forefront of our development efforts,” Raymond W. Cohen, CEO of Axonics told the press. “Patients with overactive bladder want efficacy and a long-lived solution to address their chronic condition. The Axonics R20 represents a significant breakthrough for rechargeable neuromodulation devices and underscores our commitment to continuous innovation. We are confident that Axonics’ keen focus on the incontinence patient population and increasing public awareness of sacral neuromodulation has the potential to drive significant market expansion in the years ahead.”
Axonics began sales of the R20 sacral neuromodulation system to Canadian customers. The device is currently under FDA review and the company expects approval and plans to launch the product in the U.S. in Q1 2023.
The company rolled out its F15 recharge-free sacral neuromodulator in the U.S. in April 2022.